CS1P1 PET Studies of Neuroinflammation in Parkinson Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-10

Study Completion Date

2029-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Parkinson disease (PD) is a progressive neurological disorder strongly linked to advancing age that results in decline in mobility and thinking. Based on prior research, the investigators think that small amounts of inflammation in the brain may contribute to the mobility and thinking problems in people with PD. They are trying to measure inflammation in the brain in order to understand how this inflammation could be contributing to the symptoms of PD. This study involves a brain positron emission tomography (PET) scan with a new, investigational radioactive tracer called \[11C\]-CS1P1 to identify inflammation in the brain.The goal of this project is to quantify neuroinflammation with \[11C\]-CS1P1 PET and compare to motor and cognitive function in participants with various stages of severity of PD compared to controls.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PET Imaging in Parkinson Disease Dementia

NCT01052350

Parkinson's Disease

ACTIVE_NOT_RECRUITING

PET/MR Imaging in Patients With Short and Long Standing Parkinson's Disease

NCT02801110

Idiopathic Parkinson's Disease

UNKNOWN

PET Study of Non-Motor Symptoms of Parkinson Disease

NCT01565473

Parkinson Disease

COMPLETED

Measure of Microglial Activation in the Brain of Parkinson Disease Patients With PET

NCT02319382

Parkinson's Disease With LRRK2 Mutation Healthy Controls Parkinson's Disease Without LRRK2 Mutation

UNKNOWN NA

Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls

NCT01461109

Parkinson Disease Alzheimer Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Parkinson Disease

[11C]-CS1P1

Intervention Type DRUG

Participants will receive a single intravenous bolus injection of 10.0 - 20.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a \[11C\]-CS1P1 PET scan.

Healthy Control

[11C]-CS1P1

Intervention Type DRUG

Participants will receive a single intravenous bolus injection of 10.0 - 20.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a \[11C\]-CS1P1 PET scan.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[11C]-CS1P1

Participants will receive a single intravenous bolus injection of 10.0 - 20.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a \[11C\]-CS1P1 PET scan.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Parkinson Disease (PD) participants must be at least 50 years old and meet clinical diagnostic criteria of idiopathic PD.
* Control participants must be at least 50 years old and not have PD, no first-degree family member with PD, and no evidence of PD or dementia on examination.

Exclusion Criteria

* any history of other neurologic illness (e.g. stroke, seizure, multiple sclerosis)
* history of brain surgery or major head trauma
* major medical/systemic illness
* severe psychiatric illness (e.g. bipolar disorder, schizophrenia)
* major drug abuse
* history of long term use of anti-dopaminergic medication
* chronic treatment with immunomodulatory or anti-inflammatory medications
* weight over 300 lbs
* contraindication to or inability to tolerate MRI

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes